Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.43 |
| ▸ | MMP1 | P03956 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739458 | 0.87 | MMP9 (0.52) | MMP9MMP13MMP2CA1CA2 | |
| SCHEMBL4742717 | 0.86 | MMP9 (0.57) | MMP9MMP13MMP2CA1CA2 | |
| SCHEMBL4740783 | 0.84 | CYP2D6 (0.47) | CYP2D6KCNH2 | |
| SCHEMBL4742075 | 0.81 | CYP2D6 (0.46) | MMP2CA1CA2CA9CYP2D6 | |
| SCHEMBL4742710 | 0.81 | CA1 (0.44) | MMP2CA1CA2CA9CYP2D6 | |
| SCHEMBL4741219 | 0.80 | CA1 (0.52) | MMP2CA1CA2CA9CYP2D6 | |
| SCHEMBL4743414 | 0.80 | CYP2D6 (0.51) | CYP2D6KCNH2 | |
| SCHEMBL7679570 | 0.78 | TAS1R3 (0.49) | MMP9MMP13KMT2APOLBTAS1R3 | |
| SCHEMBL4786589 | 0.78 | CYP2D6 (0.47) | CYP2D6KCNH2TAS1R3TAS1R1 | |
| SCHEMBL7675003 | 0.78 | TAS1R3 (0.49) | MMP9MMP13KMT2APOLBTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242174-B2 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | PANTHERA BIOPHARMA, LLC | 2012-06-21 | — | — | US | disclosed |
| WO-2008094592-A1 | HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094592-A1 | HYDROXAMIC ACID DERIVATIVES OF ANILINE USEFUL AS THERAPEUTIC AGENTS FOR TREATING ANTHRAX POISONING | PANTHERA BIOPHARNA, LLC (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157462-A1 | Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning | ANTXR2, AGXT, AADAC | MMP9 809/4885MMP13 391/4885MMP2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.